文献速递临床试验与 GCP基础与转化研究

阿达木单抗治疗坐骨神经痛随机对照试验提前终止的经验教训

Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC).
PubMed 文献 · Trials · 2018-07-31

本文描述了一项在6个英国中心开展的实用型随机对照试验,旨在比较阿达木单抗皮下注射与安慰剂对接受物理治疗的坐骨神经痛患者的疗效,主要结局为Oswestry功能障碍指数。计划样本量332例,但内部预试验阶段因招募缓慢(仅2个中心活跃、招募8例)在开放10个月后终止,文章总结了合同延迟、中心退出、超额治疗费用获取困难等挑战。

要点

  • 针对坐骨神经痛的生物制剂随机对照试验因招募低效在预试验阶段提前终止。
  • 试验计划样本量332例,实际仅招募8例,主要原因为运营问题与参与者接受度低。
  • 合同延迟、中心退出及超额治疗费用获取困难是试验启动和招募的主要障碍。

核心结论

  • 在坐骨神经痛患者中开展阿达木单抗随机对照试验面临合同延迟、中心退出、费用获取困难及招募缓慢等多重挑战,导致预试验阶段提前终止。
  • 仍需要开展肿瘤坏死因子α阻断剂的随机对照试验以确定其在严重坐骨神经痛中的成本效果。

研究设计与样本

  • 实用型、平行组、随机对照试验,对参与者、临床医生、结局评估和统计分析设盲,在英国6个中心开展。
  • 参与者随机接受两剂阿达木单抗(80 mg,2周后40 mg)或生理盐水安慰剂皮下注射于后外侧大腿,两组均转诊接受物理治疗。
  • 主要结局为Oswestry功能障碍指数评估的残疾,计划样本量332例,前50例进入内部预试验阶段。

主要发现

  • 内部预试验阶段在开放10个月后因招募低效终止,仅2个中心活跃,共招募8例参与者。
  • 挑战包括合同延迟(1个中心未完成合同谈判,2个中心在试验关闭前不久签约)、中心因患者安全担忧退出、超额治疗费用获取困难。
  • 在招募的两个中心,因运营问题和潜在参与者接受度低,招募速度慢于计划。

关键数值与推荐

  • 计划样本量332例,前50例为内部预试验阶段;实际仅招募8例。
  • 阿达木单抗剂量方案为80 mg皮下注射,2周后40 mg;对照组为生理盐水安慰剂。
  • 主要结局测量时间点为基线、6周、6个月和12个月随访。

临床怎么用

  • 在严重坐骨神经痛中引入生物制剂等治疗变革时,需额外开展准备工作以应对合同、费用和招募等复杂问题。
  • 临床研究应在能够实际提供治疗的环境中开展,以改善患者照护。

局限性

  • 试验提前终止,未能获得主要结局数据。
  • 仅2个中心活跃,招募8例,样本量远低于计划。
  • 合同延迟、中心退出和费用问题影响了试验启动和招募。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adalimumab, a biological treatment targeting tumour necrosis factor α, might be useful in sciatica. This paper describes the challenges faced when developing a new treatment pathway for a randomised controlled trial of adalimumab for people with sciatica, as well as the reasons why the trial discussed was stopped early. METHODS: A pragmatic, parallel group, randomised controlled trial with blinded (masked) participants, clinicians, outcome assessment and statistical analysis was conducted in six UK sites. Participants were identified and recruited from general practices, musculoskeletal services and outpatient physiotherapy clinics. They were adults with persistent symptoms of sciatica of 1 to 6 months' duration with moderate to high level of disability. Eligibility was assessed by research physiotherapists according to clinical criteria, and participants were randomised to receive two doses of adalimumab (80 mg then 40 mg 2 weeks later) or saline placebo subcutaneous injections in the posterior lateral thigh. Both groups were referred for a course of physiotherapy. Outcomes were measured at baseline, 6-week, 6-month and 12-month follow-up. The main outcome measure was disability measured using the Oswestry Disability Index. The planned sample size was 332, with the first 50 in an internal pilot phase. RESULTS: The internal pilot phase was discontinued after 10 months from opening owing to low recruitment (two of the six sites active, eight participants recruited). There were several challenges: contractual delays; one site did not complete contract negotiations, and two sites signed contracts shortly before trial closure; site withdrawal owing to patient safety concerns; difficulties obtaining excess treatment costs; and in the two sites that did recruit, recruitment was slower than planned because of operational issues and low uptake by potential participants. CONCLUSIONS: Improved patient care requires robust clinical research within contexts in which treatments can realistically be provided. Step changes in treatment, such as the introduction of biologic treatments for severe sciatica, raise complex issues that can delay trial initiation and retard recruitment. Additional preparatory work might be required before testing novel treatments. A randomised controlled trial of tumour necrosis factor-α blockade is still needed to determine its cost-effectiveness in severe sciatica. TRIAL REGISTRATION: Current Controlled Trials, ISRCTN14569274 . Registered on 15 December 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Williams NH, Jenkins A, Goulden N, et al. Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC). Trials. 2018. PMID: 30064491. doi:10.1186/s13063-018-2801-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。